Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is a gynecological malignancy that is associated with high mortality. Annexin A10 (ANXA10) is variably expressed in several types of human malignancy, but its role and clinical significance in EOC remain unknown. This study aimed to investigate the role of ANXA10 in EOC cells in vitro and to study the association between the protein expression levels of the ANXA10 in tumor tissue from patients with serous EOC and clinical outcome.

MATERIAL AND METHODS: The expression of ANXA10 was studied in 118 cases of serous EOC and in the ovarian cancer cell lines, SKOV-3, HO9810, HO8910PM, and OVCAR3 with immunohistochemistry and Western blot. Correlation between ANXA10 expression and clinicopathological variables and patient outcome were evaluated, including with Kaplan-Meier survival curves, univariate analysis with the log-rank test, and the multivariate analysis with the Cox-regression model.

RESULTS: ANXA10 was expressed by cells in the ovarian cancer cell lines. Patients with low expression and high expression of ANXA10 were 61.86% (73/118) and 38.14% (45/118), respectively. High expression of ANXA10 was correlated with poor response to chemotherapy (P=0.034), the presence of lymphatic invasion (P=0.043), and the International Federation of Gynecology and Obstetrics (FIGO) advanced stage (P=0.033), which were all associated with lower survival rates of serous EOC. Increased expression of ANXA10 was identified as an independent prognostic biomarker of serous EOC (HR=1.73; 95% CI, 1.01–2.98; P=0.046).

CONCLUSIONS: Increased expression of ANXA10 was an independent prognostic marker in patients with serous EOC.

Keywords: Annexins, Chemotherapy, Adjuvant, Neoplasm Invasiveness, Ovarian Neoplasms, Prognosis, Adult, Aged, Apoptosis, Biomarkers, Pharmacological, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Gene Expression, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Survival Rate